167 related articles for article (PubMed ID: 37265174)
1. Dextromethorphan/quinidine for the treatment of bulbar impairment in amyotrophic lateral sclerosis.
Tabor Gray L; Locatelli E; Vasilopoulos T; Wymer J; Plowman EK
Ann Clin Transl Neurol; 2023 Aug; 10(8):1296-1304. PubMed ID: 37265174
[TBL] [Abstract][Full Text] [Related]
2. Swallowing Safety and Efficiency Impairment Profiles in Individuals with Amyotrophic Lateral Sclerosis.
Robison R; DiBiase L; Ashley A; McElheny K; Anderson A; Wymer JP; Plowman EK
Dysphagia; 2022 Jun; 37(3):644-654. PubMed ID: 34037850
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.
Smith R; Pioro E; Myers K; Sirdofsky M; Goslin K; Meekins G; Yu H; Wymer J; Cudkowicz M; Macklin EA; Schoenfeld D; Pattee G
Neurotherapeutics; 2017 Jul; 14(3):762-772. PubMed ID: 28070747
[TBL] [Abstract][Full Text] [Related]
4. Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysis.
Green JR; Allison KM; Cordella C; Richburg BD; Pattee GL; Berry JD; Macklin EA; Pioro EP; Smith RA
Br J Clin Pharmacol; 2018 Dec; 84(12):2849-2856. PubMed ID: 30152872
[TBL] [Abstract][Full Text] [Related]
5. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.
James E; Ellis C; Brassington R; Sathasivam S; Young CA
Cochrane Database Syst Rev; 2022 May; 5(5):CD006981. PubMed ID: 35593746
[TBL] [Abstract][Full Text] [Related]
6. Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (Center for Neurologic Study Bulbar Function Scale).
Smith RA; Macklin EA; Myers KJ; Pattee GL; Goslin KL; Meekins GD; Green JR; Shefner JM; Pioro EP
Eur J Neurol; 2018 Jul; 25(7):907-e66. PubMed ID: 29577526
[TBL] [Abstract][Full Text] [Related]
7. Profiles of Dysarthria and Dysphagia in Individuals With Amyotrophic Lateral Sclerosis.
Donohue C; Gray LT; Anderson A; DiBiase L; Wymer JP; Plowman EK
J Speech Lang Hear Res; 2023 Jan; 66(1):154-162. PubMed ID: 36525626
[TBL] [Abstract][Full Text] [Related]
8. Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis.
Sancho J; Ferrer S; Burés E; Luis Díaz J; Torrecilla T; Signes-Costa J; Servera E
Respir Med; 2021 Sep; 186():106536. PubMed ID: 34260979
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity and specificity of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised to detect dysarthria in individuals with amyotrophic lateral sclerosis.
Donohue C; Chapin JL; Anderson A; DiBiase L; Gray LT; Wymer JP; Plowman EK
Muscle Nerve; 2023 Sep; 68(3):296-302. PubMed ID: 37345346
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of the amyotrophic lateral sclerosis Functional Rating Scale-Revised to detect pharyngeal dysphagia in individuals with amyotrophic lateral sclerosis.
Chapin JL; Gray LT; Vasilopoulos T; Anderson A; DiBiase L; York JD; Robison R; Wymer J; Plowman EK
PLoS One; 2020; 15(8):e0236804. PubMed ID: 32790801
[TBL] [Abstract][Full Text] [Related]
11. A clinical bulbar assessment scale (CBAS) for amyotrophic lateral sclerosis.
Ball LJ; Geske JA; Burton E; Pattee GL
Muscle Nerve; 2022 Dec; 66(6):694-701. PubMed ID: 36217681
[TBL] [Abstract][Full Text] [Related]
12. Dysphagia in Amyotrophic Lateral Sclerosis: Relationships between disease progression and Fiberoptic Endoscopic Evaluation of Swallowing.
Fattori B; Siciliano G; Mancini V; Bastiani L; Bongioanni P; Caldarazzo Ienco E; Barillari MR; Romeo SO; Nacci A
Auris Nasus Larynx; 2017 Jun; 44(3):306-312. PubMed ID: 27569290
[TBL] [Abstract][Full Text] [Related]
13. Lingual and Jaw Kinematic Abnormalities Precede Speech and Swallowing Impairments in ALS.
Perry BJ; Martino R; Yunusova Y; Plowman EK; Green JR
Dysphagia; 2018 Dec; 33(6):840-847. PubMed ID: 29774424
[TBL] [Abstract][Full Text] [Related]
14. ALSUntangled #71: Nuedexta.
Sun Y; Benatar M; Mascías Cadavid J; Ennist D; Wicks P; Staats K; Beauchamp M; Jhooty S; Pattee G; Brown A; Bertorini T; Barkhaus P; Bromberg M; Carter G; Bedlack R; Li X
Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):218-222. PubMed ID: 37493197
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of Dysphagia Based on the Type of ALS in Korean Patients Evaluated Using Videofluoroscopic Study: A Retrospective Analysis.
Park YC; Lee JY; Lee JS; Park JS; Oh KW; Kim SH; Kim MJ
Dysphagia; 2022 Dec; 37(6):1748-1756. PubMed ID: 35304623
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
17. Speech timing and monosyllabic diadochokinesis measures in the assessment of amyotrophic lateral sclerosis in Canadian French.
Bouvier L; McKinlay S; Truong J; Genge A; Dupré N; Dionne A; Kalra S; Yunusova Y
Int J Speech Lang Pathol; 2024 Apr; 26(2):267-277. PubMed ID: 37272348
[TBL] [Abstract][Full Text] [Related]
18. Dextromethorphan/quinidine: in pseudobulbar affect.
Garnock-Jones KP
CNS Drugs; 2011 May; 25(5):435-45. PubMed ID: 21476614
[TBL] [Abstract][Full Text] [Related]
19. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
[TBL] [Abstract][Full Text] [Related]
20. Effects of Aided Communication on Communicative Participation for People With Amyotrophic Lateral Sclerosis.
Peters B; Wiedrick J; Baylor C
Am J Speech Lang Pathol; 2023 Jul; 32(4):1450-1465. PubMed ID: 37335771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
